Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

70.85 +0.72 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,555,420
Open 70.43
Bid (Size) 70.70 (1)
Ask (Size) 70.82 (1)
Prev. Close 70.13
Today's Range 70.16 - 71.10
52wk Range 60.47 - 76.56
Shares Outstanding N/A
Dividend Yield 1.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
These are the undervalued pharmaceutical stocks to buy as they have a deep clinical pipeline which will driven earnings and cash flow growth. 
Via InvestorPlace
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
Why Quality-Oriented Investors Should Consider NASDAQ:AZN. 
Via Chartmill

Performance

YTD
+3.58%
+3.58%
1 Month
+7.58%
+7.58%
3 Month
+5.53%
+5.53%
6 Month
+12.37%
+12.37%
1 Year
-6.54%
-6.54%

More News

Read More
European Stock: AstraZeneca
Via Talk Markets
Looking At AstraZeneca's Recent Unusual Options Activity
Via Benzinga
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Via Benzinga
Topics Brexit
Exposures Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
Via InvestorPlace
Topics Economy
Exposures Interest Rates
A Closer Look at AstraZeneca's Options Market Dynamics
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
From AstraZeneca
Via Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Via The Motley Fool
Topics Stocks
Exposures US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
Via Benzinga
Exposures Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
From AstraZeneca
Via Business Wire
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Via Benzinga
Exposures Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
Via Benzinga
Topics Economy
Exposures Interest Rates
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
From Daiichi Sankyo
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
From AstraZeneca
Via Business Wire
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial
Via Benzinga
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.